复方皂矾丸在鼻咽癌同步放化疗中的应用研究  被引量:3

Clinical Application of Complex Zaofan Pills in Concurrent Chemotherapy and Radiotherapy on Nasopharyngeal Carcinoma

在线阅读下载全文

作  者:熊锐华[1] 田秀荣[1] 任庆[1] 唐新云[1] 

机构地区:[1]中国人民解放军第一八一医院肿瘤治疗中心,广西桂林市541002

出  处:《临床合理用药杂志》2011年第06X期31-32,共2页Chinese Journal of Clinical Rational Drug Use

摘  要:目的探讨复方皂矾丸在鼻咽癌同步放化疗中对骨髓造血功能的保护。方法 160例Ⅱ~Ⅳa期鼻咽癌患者,随机分为治疗组(复方皂矾丸+同步放化疗)80例,对照组(同步放化疗)80例,两组均在根治性放疗的同时给予顺铂100mg/m2,D1、D22、D43化疗,治疗组同时给予复方皂矾丸口服,对照组不给予特殊处理。结果治疗组和对照组在近期疗效、胃肠道反应、肝肾功能损害方面差异无统计学意义(P>0.05),而在同步放化疗导致的白细胞下降、贫血、血小板下降方面,治疗组的发生率和程度均低于对照组,差异有统计学意义(P<0.05)。结论复方皂矾丸在鼻咽癌同步放化疗中应用,可有效预防和治疗同步放化疗导致的骨髓抑制,保证同步放化疗的顺利进行,值得进一步推广。Objective To explore the protection of Complex Zaofan Pills to marrow blood - producing function in Con- current Chemotherapy and Radiotherapy on nasopharyngeal carcinoma. Methods A total of 160 patients with stage 11 - 1Va na- sopharyngeal carcinoma were randomized into the A group (Complex Zaofan Pills plus Concurrent Chemotherapy and Radiothera- py) and B group (Concurrent Chemotherapy and Radiotherapy) , 80 patients each group. The two groups of patients received Concurrent Chemotherapy and Radiotherapy chemotherapy regime: DDP 100mg/m2 D1, D22, 1)43. At the same time, group A was treated by Complex Zaofan Pills. Results The Short -term curative effect and side effects in gastrointestinal reaction, liver and nephridium had no significant difference fietween the two groups, while the incidence rate and level of leucopenia, ane- mia and thrombocytopenia coursed by Concurrent^hemotherapy and Radiotherapy in group A are lower than in group B, with a significant difference between the two groups ConClusion Complex Zaofan Pills used in Concurrent Chemotherapy and Radiother- apy on nasopharyngeal carcinoma could prevent.and cure bone marrow depression and worth luther widely using.

关 键 词:鼻咽肿瘤 复方皂矾丸 放射疗法 化学疗法 

分 类 号:R739.63[医药卫生—肿瘤]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象